Dr. Bredesen will present the results of his proof-of-concept trial, “Precision Medicine for Cognitive Decline: Successful Proof-of-Concept Trial,” with co-authors Dr.’s Kat Toups, Ann Hathaway, and Deborah Gordon at the IFM’s Advancements in Clinical Research and Innovative Practices (AIC) in Functional Medicine conference, which highlights new research in functional medicine and its clinical applications from June 3rd to 5th.

On Saturday, June 5th at 7:00 am PT, Drs. Dale Bredesen, Kat Toups, Ann Hathaway, and Deborah Gordon will make their presentation on the first clinical trial to identify and target the specific drivers of cognitive decline for each patient with a precision medicine protocol, instead of attempting to treat Alzheimer’s or MCI without determining what is causing the cognitive decline.

Share This: